Drug Trial Radar · NCT07213973
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Mar 25, 2028
Study completion Mar 25, 2028
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
PovorcitinibDrug
Oral; Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline through Week 54
- Apparent clearanceTime frame: Up to Week 24
- Apparent volume of distributionTime frame: Up to Week 24
- Apparent oral absorption rate constantTime frame: Up to Week 24
- Absorption lag timeTime frame: Up to Week 24
- Maximum plasma drug concentration at steady stateTime frame: Up to Week 24
- Average plasma drug concentration at steady stateTime frame: Up to Week 24
- Plasma concentration at steady state for the dosing intervalTime frame: Up to Week 24
- Time to maximum plasma concentration at steady stateTime frame: Up to Week 24
- Terminal half-lifeTime frame: Up to Week 24
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham
Birmingham, Alabama · Recruiting
Medical Dermatology Specialists Phoenix
Phoenix, Arizona · Recruiting
Saguaro Dermatology
Phoenix, Arizona · Recruiting
Uconn Health
Farmington, Connecticut · Recruiting
University of Miami Miller School of Medicine
Miami, Florida · Recruiting
Skin Research of South Florida, Llc
Miami, Florida · Recruiting
Trueblue Clinical Research
Tampa, Florida · Recruiting
Advanced Medical Research Pc
Sandy Springs, Georgia · Recruiting
Endeavor Health Medical Group
Skokie, Illinois · Recruiting
Dermatology Skin Cancer Center Leawood
Leawood, Kansas · Recruiting
Equity Medical
Bowling Green, Kentucky · Recruiting
Johns Hopkins Univ Schl of Medicine
Baltimore, Maryland · Recruiting
Boston Childrens Hospital
Boston, Massachusetts · Recruiting
Oakland Hills Dermatology Pc
Auburn Hills, Michigan · Recruiting
Wayne State University Physician Group Dermatology
Detroit, Michigan · Recruiting
Revival Research Institute, Llc Troy
Troy, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
Boeson Research Missoula 2825 Fort Missoula Rd
Missoula, Montana · Recruiting
University of New Mexico Hospital
Albuquerque, New Mexico · Recruiting
Geisinger Medical Center
Danville, Pennsylvania · Recruiting
Bellaire Dermatology Associates Bda
Bellaire, Texas · Recruiting
Texas Dermatology Research Center
Dallas, Texas · Recruiting
3A Research Llc West Location
El Paso, Texas · Recruiting
Jordan Valley Dermatology Center
South Jordan, Utah · Recruiting
Skincare Studio Dermatology Centre
St. John's, Canada · Recruiting
Dermcare Clinic
Mississauga, Ontario, Canada · Recruiting
York Dermatology Center
Richmond Hill, Ontario, Canada · Recruiting
The Hospital For Sick Children
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.